Promising new finding for therapies to treat persistent seizures in epileptic patients

January 16, 2013
Photos depict NMDA receptors moving to the neuron surface during status epilepticus (SE), persistent seizures. The NMDA receptors are in red (NR1), and the cell surface marker is in green (synaptophysin). When they are at the same location (cell surface), the overlap of red and green becomes yellow. The existence of more yellow with SE suggests many more surface NMDA receptors, which can serve as targets for new medication. Credit: Dr. David E. Nayor

In a promising finding for epileptic patients suffering from persistent seizures known as status epilepticus, researchers reported today that new medication could help halt these devastating seizures. To do so, it would have to work directly to antagonize NMDA receptors, the predominant molecular device for controlling synaptic activity and memory function in the brain.

"Despite the development of new medications to prevent seizures, status epilepticus remains a life-threatening condition that can cause extensive brain damage in the patients that survive these persistent seizures," said David E. Naylor, MD, PhD, a lead researcher at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and corresponding author of the new study. "Our research holds promise for the development of new therapies to treat this devastating condition because we have found a potential new for medical intervention that should bolster the current standard therapies to treat the acute seizures. It may also prevent the long-term adverse effects of persistent seizure activity on the brain."

The research, reported online in the Neurology of Disease journal, used animal models to assess cellular activity in the brain during persistent seizures. It found that the seemed to force the NMDA receptors from the interior to the surface of causing their activity to increase by approximately 38%.

"The increased presence of the NMDA receptors on the cell surface during these seizures may explain the successful use of NMDA antagonists – medication that inhibits the activity of the NMDA receptors in the brain – in the latter stages of a seizure, long after other medications have stopped working," said Dr. Naylor. "We concluded that medications that suppress the activity of the NMDA receptors, in conjunction with other medications, may be successful in stopping . Further research is, of course, needed."

Explore further: New drug target for Alzheimer's, stroke discovered

More information: www.sciencedirect.com/science/article/pii/S0969996113000065

Related Stories

New drug target for Alzheimer's, stroke discovered

October 11, 2011

A tiny piece of a critical receptor that fuels the brain and without which sentient beings cannot live has been discovered by University at Buffalo scientists as a promising new drug target for Alzheimer's and other neurodegenerative ...

Recommended for you

Fast and slow—learning how the brain controls movement

May 4, 2016

What if you couldn't move faster even when you wanted to? Researchers thought that the part of the brain that determines how fast we perform voluntary movements, such as walking across a room or playing a melody on the piano, ...

Aggregated protein in nerve cells can cause ALS

May 4, 2016

Persons with the serious disorder ALS, can have a genetic mutation that causes the protein SOD1 to aggregate in motor neurons in the brain and spinal cord. Researchers at Umeå University have discovered that, when injected ...

Adult brain prunes branched connections of new neurons

May 2, 2016

When tweaking its architecture, the adult brain works like a sculptor—starting with more than it needs so it can carve away the excess to achieve the perfect design. That's the conclusion of a new study that tracked developing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.